Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments

Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today recognizes Blood Cancer Awareness Month by highlighting its strategic investments and tenants developing life-saving therapies in hematology and oncology, as well as the company's longstanding mission-critical engagement with the nation's leading nonprofits focused on blood cancers. Blood cancers, also known as hematologic cancers, begin in blood-forming tissue, such as bone marrow, or in cells of the immune system. There are over 100 types of blood cancers, including leukemia, lymphoma and myeloma. "According to Blood Cancer United, someone is diagnosed with leukemia, lymphoma or myeloma approximately every three minutes, representing 9.4% of all new cancers in the United States in 2025. And they remain a major cause of cancer mortality; someone in the U.S. dies from blood cancer approximately every nine minutes. There has been meaningful progress, and survival rates have improved substantially with over one million people in the U.S. living with or in remission from blood cancers, but continued investment and collaboration remain essential," said Peter Moglia, chief executive officer and chief investment officer of Alexandria Real Estate Equities, Inc. "Blood Cancer Awareness Month is more than a moment for recognition and reflection; it is a call to action to accelerate research, improve access and support patients and families. We are honored to partner with consequential nonprofit organizations focused on oncology and hematology, and deeply proud of Alexandria's mission-critical role in enabling our tenants and investments to develop life-changing treatments and cures." Juno Therapeutics (Juno), Alexandria's longstanding tenant in Seattle, represents one of the defining success stories in blood cancer innovation. An early leader in CAR-T therapies, Juno helped advance the science behind Breyanzi®, one of the leading FDA-approved CAR-T cell therapies for relapsed or refractory B-cell blood cancers, with approvals across multiple lymphoma indications and marketed by Bristol Myers Squibb. Alexandria Venture Investments was also an early investor in Juno, which went public in 2014 at an IPO market capitalization of approximately $2.2 billion and was acquired by Celgene in 2018; Celgene was later acquired by Bristol Myers Squibb in 2019. For over a decade, Alexandria has engaged with nonprofits advancing research, patient advocacy and access across oncology and hematology, including the Multiple Myeloma Research Foundation (MMRF), Blood Cancer United, the National Marrow Donor Program (NMDP), Alliance for Cancer Gene Therapy, Fred Hutch Cancer Center, Curebound, UCSD Health's Moores Cancer Center and Memorial Sloan Kettering Cancer Center. In 2012, Alexandria began its partnership with the MMRF, the largest nonprofit solely focused on accelerating a cure for multiple myeloma patients, with Joel Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc., serving on its board from 2014 to 2017. Alexandria is proud to support the MMRF at the nonprofit's Blood Cancer Awareness event at the Alexandria Center® for Life Science – New York City megacampus this month. Through Alexandria's corporate social responsibility initiatives, the company and its employees also support NMDP, formerly Be The Match, a global nonprofit leader in cell therapy that connects patients to life-saving donors and advances research to improve patient outcomes. Alexandria employees may use company-provided Volunteer Time Off to donate blood, platelets or bone marrow, and the company regularly coordinates blood drives across its collaborative campuses for both its employees and tenants.